<DOC>
	<DOCNO>NCT03005366</DOCNO>
	<brief_summary>- The main objective project study efficacy mechanistic value block atrial specific atria-preferential dynamic ionic current terminate paroxysmal atrial fibrillation ( AF ) . - The hypothesis drug block atrial specific atria-preferential dynamic ionic current ( IK , ACh - acetylcholine sensitive K+ current - INa - inward sodium current - , respectively ) effective terminate paroxysmal AF episodes fast atrial activation rate , classical INa blocker , effective terminate AF episodes slow activation rate . - The investigator include patient without structural heart disease short-lasting AF episode ( &lt; 48 h. ) . Double blind single center study , patient randomly assign cardioversion group use intravenous flecainide atria-preferential atrial-specific blockade group use intravenous vernakalant . Patients routinely monitor electrophysiology room acquire 12-lead digitize ECG signal non-invasive body surface potential mapping . Atrial signal extract multisite body surface ECG recording obtain temporal spectral parameter , measure organization atrial rate group . The result obtain clinical setting study mathematical model understand capability terminate paroxysmal AF . The project expect provide consistent , reliable reproducible parameter assist clinician know type paroxysmal AF episodes suitable effectively terminate , upon administration drug atrial specific atria-preferential profile .</brief_summary>
	<brief_title>Predictive Factors Effectively Terminate Paroxysmal Atrial Fibrillation Blocking Atrial Selective Ionic Currents</brief_title>
	<detailed_description>- Background : Different research strategy aim understand mechanism underlie maintenance atrial fibrillation ( AF ) , prevent ventricular pro-arrhythmia relate use anti-arrhythmic drug restore sinus rhythm . Such aim might achieve drug effectively terminate reentrant source identify AF , along atrial specific atria-preferential blockade ionic current . The latter may especially relevant paroxysmal AF episode fast atrial activation rate , INa IK , ACh involve maintenance fast atrial reentrant source underlie AF . - Objective : The main objective project study efficacy mechanistic value block atrial specific atria-preferential dynamic ionic current terminate paroxysmal AF . - The hypothesis drug block atrial specific atria-preferential dynamic ionic current ( IK , ACh INa , respectively ) effective terminate paroxysmal AF episodes fast atrial activation rate , classical INa blocker , effective terminate AF episodes slow activation rate . - Design : Double blind single center study , patient randomly assign cardioversion group use intravenous flecainide atria-preferential atrial-specific blockade group use intravenous vernakalant . Patients routinely monitor electrophysiology room 90 minute upon drug administration acquire 12-lead digitize ECG signal non-invasive body surface potential mapping . Body surface recording conventional ECG signal export obtain temporal spectral parameter atrial activity AF , measure organization atrial rate group patient undergo pharmacological cardioversion . The success rate cardioversion obtain group correlate pattern activation spectral parameter obtain body surface , provide type paroxysmal AF episodes suitable terminate upon administration anti-arrhythmic drug atrial specific atria-preferential profile . Electrical cardioversion perform subject unsuccessful pharmacological cardioversion within first 24 h. vernakalant flecainide administration . The result obtain clinical setting study realistic mathematical model understand capability drug terminate paroxysmal AF .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>1 . Patients ≥ 20 ≤65 yearolds . 2 . Patients paroxysmal AF lasting &lt; 48 hour , pharmacological cardioversion may indicate . 3 . Hemodynamically stable patient ( systolic blood pressure &gt; 100 mm Hg &lt; 160 mm Hg . Diastolic blood pressure &lt; 95 mm Hg ) . 4 . Weight 45136 kg . 5 . Appropriate anticoagulation therapy accord clinical practice guideline European Society Cardiology paroxysmal AF episodes lasting &lt; 48 hour . 6 . Signed informed consent . 1 . Corrected QT interval &gt; 440 millisecond , long QT family history 'Torsades de Pointes ' syndrome . 2 . Symptomatic bradycardia ventricular rate &lt; 50 bpm without pacemaker , QRS interval &gt; 140 millisecond . 3 . Patients heart failure regardless classification New York Heart Association ( NYHA ) . 4 . Second third degree atrioventricular block , right bundle branch block associate partial leave bundle branch block ( bifascicular block ) . 5 . Cardiogenic septic shock , chronic myocardial infarction , acute coronary syndrome , heart surgery previous 30 day inclusion . 6 . Valvular stenosis , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis . 7 . Previous unsuccessful electrical cardioversion longstanding atrial fibrillation ( attempt convert sinus rhythm ) . 8 . Treatment investigational drug within 60 day enrollment . 9 . Previous treatment vernakalant . 10 . Secondary cause atrial fibrillation , hyperthyroidism , uncorrected electrolyte imbalance , digoxin toxicity . 11 . IV / oral treatment Class I III antiarrhythmic ( except amiodarone ) previous 48 hour . 12 . Renal failure glomerular filtration rate &lt; 35 ml / min . 13 . Intravenous / oral amiodarone within previous 3 month . 14 . Pregnant nursing woman . 15 . Intolerance allergy two drug study . 16 . Refusal sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>vernakalant</keyword>
	<keyword>flecainide</keyword>
	<keyword>cardioversion</keyword>
</DOC>